The Oncology Institute Inc Revenue Growth Rates (TOI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
The Oncology Institute Inc   (NASDAQ: TOI)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

TOI's Revenue Growth by Quarter and Year

The Oncology Institute Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TOI/growth
https://api.csimarket.com/api/v1/companies/TOI/fundamentals
https://api.csimarket.com/api/v1/companies/TOI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
TOI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 169.77
2nd Quarter June 161.28
1st Quarter March 147.44
FY 478.49

TOIs Annual Revenue
The Oncology Institute Inc 's Revenue in the fiscal year 2025 $ 502.73 millions
The Oncology Institute Inc 's Revenue in the fiscal year 2024 $ 393.41 millions
The Oncology Institute Inc 's Revenue in the fiscal year 2023 $ 324.24 millions
The Oncology Institute Inc 's Revenue in the fiscal year 2022 $ 252.48 millions
The Oncology Institute Inc 's Revenue in the fiscal year 2021 $ 203.00 millions




TOI Revenue third quarter 2026 Y/Y Growth Comment
The Oncology Institute Inc reported Revenue improvement of 24.32% year on year in the third quarter 2026, to $ 169.77 millions, this is lower than The Oncology Institute Inc 's recent average Revenue improvement of 26.92%.

Looking into third quarter 2026 results within Healthcare Facilities industry 2 other companies have achieved higher Revenue growth. While The Oncology Institute Inc ' s Revenue rise of 24.32% ranks overall at the positon no. 656 in the third quarter 2026.


TOI Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 24.32 %
2nd Quarter June 34.62 %
1st Quarter March 41.21 %
FY   -

Financial Statements
The Oncology Institute Inc 's third quarter 2026 Revenue $ 169.77 millions TOI's Income Statement
The Oncology Institute Inc 's third quarter 2025 Revenue $ 136.56 millions Quarterly TOI's Income Statement


TOI Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.26 %
2nd Quarter June 9.39 %
1st Quarter March 3.86 %
FY (Year on Year)   -


Back to TOI Growth rate Comparisons >> Back to TOI Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #3
Healthcare Sector #154
Overall #656

Revenue Y/Y Growth Statistics
High Average Low
41.58 % 26.92 % 10.29 %
(Jun 30 2026)   (Dec 31 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #3
Healthcare Sector #154
Overall #656
Revenue Y/Y Growth Statistics
High Average Low
41.58 % 26.92 % 10.29 %
(Jun 30 2026)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

The Oncology Institute Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
14.75 % 5.96 % 0.06 %
(Jun 30 2025)  


TOI's III. Quarter Q/Q Revenue Comment
The Oncology Institute Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.26% quarter on quarter, to $ 169.77 millions.

Within Healthcare Facilities industry 6 other companies have achieved higher Revenue quarter on quarter growth. While The Oncology Institute Inc 's Revenue growth quarter on quarter, overall rank is 847.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #7
Healthcare Sector #127
Overall #847
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #7
Healthcare Sector #127
Overall #847
Revenue Q/Q Growth Statistics
High Average Low
14.75 % 5.96 % 0.06 %
(Jun 30 2025)  


TOI's III. Quarter Q/Q Revenue Comment
The Oncology Institute Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.26% quarter on quarter, to $ 169.77 millions.

Within Healthcare Facilities industry 6 other companies have achieved higher Revenue quarter on quarter growth. While The Oncology Institute Inc 's Revenue growth quarter on quarter, overall rank is 847.


The Oncology Institute Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 587.24
Y / Y Revenue Growth (TTM) 38.38 %
Year on Year Revenue Growth Overall Ranking # 963
Seqeuential Revenue Change (TTM) 7.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 2016


Cumulative Revenue growth Comment
With 38.38% annual Revenue growth, The Oncology Institute Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 187 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 742 to 963.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 23
Healthcare Sector # 188
Overall # 963

Revenue TTM Y/Y Growth Statistics
High Average Low
38.38 %
 12.39 %
-28.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 312
S&P 500 # 2016
Cumulative Revenue growth Comment
With 38.38% annual Revenue growth, The Oncology Institute Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 187 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 742 to 963.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 23
Healthcare Sector # 188
Overall # 963

Revenue TTM Y/Y Growth Statistics
High Average Low
38.38 %
12.39 %
-28.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 312
S&P 500 # 2016




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TOI's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions


About The Oncology Institute Inc Revenue Growth Rates (TOI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Starling Oncology Inc (CIK 1799191).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001799191-26-000023
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Starling Oncology Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.